AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via 2 hour IV infusion, single dose
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via 2 hour IV infusion, 6 doses over 22 days
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via SC injection, single dose
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 50 mg via SC injection, 6 doses over 22 days
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via 2 hour IV infusion, single dose
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via 2 hour IV infusion, single dose
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via SC injection, single dose
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via SC injection, single-dose
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via 2 hour IV infusion, 6 doses over 22 days
Study NCT01930812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Sodium Fluoride (NaF)
Description: A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
Study NCT02446353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES / Megace
Description: Sequences of administered drugs
Study NCT02979730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Lab Test
Description: For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
Study NCT02979730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ED Point of Care Test
Description: For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
Study NCT01367301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT01367301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT01367301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy
Study NCT01367301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Description: Undergo HDR brachytherapy
Study NCT01367301 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT
Study NCT01367301 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04585217 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized laterality of suture materials for closure (6-0 polypropylene monofilament suture vs fast absorbing gut suture on right eyelid)
Description: Plain gut suture (6-0 fast absorbing plain gut \[Sharpoint Express gut TM\]) and polypropylene suture (6-0 polypropylene \[Ethicon Prolene TM\]) will be used to close blepharoplasty incisions. Each patient will have one eyelid using plain gut suture and the other eyelid with polypropylene suture. Each subject will be randomized as to laterality.
Study NCT01672437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth and parent preparation
Description: 4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
Study NCT00796601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esreboxetine
Description: Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
Study NCT00796601 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film coated tablets (0 mg esreboxetine), once daily for 6 months
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via 2 hour IV infusion, 6 doses over 22 days
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via SC injection, 6 doses over 22 days
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via SC injection, 6 doses over 22 days
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
Study NCT00734240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 353512
Description: 2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
Study NCT05181748 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelet rich plasma
Description: Preparation of PRP will be performed immediately following blood sample collection. Blood samples will be collected from the median antebrachial vein. PRP will be prepared according to the manufacturer's instructions employing a Regen Autologous Cellular Regeneration (ACR®-C) Kit (Regen Laboratory, Le Mont-sur-Lausanne, Switzerland). Approximately 60 mL of the patient's peripheral blood will be required in order to yield the required volume of PRP. The goal concentration of platelets in PRP is approximately 1.000.000 platelets/µL. The technique of PRP intraovarian infusion resembles the transvaginal paracentesis performed during the oocyte pick-up procedure. Briefly, both ovaries are visualized via transvaginal ultrasound monitoring, and they are intramedullary injected on multiple sites using a 17-gauge single lumen needle, with the patient under inhaled minimal sedation.
Study NCT00893048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone, 60 mg, one time at time of diagnosis
Study NCT00893048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo
Study NCT02548572 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcorneal Electrical Stimulation using Okustim device
Description: The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).
Study NCT02548572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation using Okustim device
Description: The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device).
Study NCT01782456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Oral Nutritional Supplement
Description: Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
Study NCT00813449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine plus Endostar (Experimental group)
Description: dacarbazine plus Endostar
Study NCT00813449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dacarbazine plus placebo (control group)
Description: dacarbazine plus placebo
Study NCT00783133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Description: Clarinex 5 mg daily x 7 days
Study NCT00783133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fexofenadine
Description: Allegra 180 mg daily x 7 days
Study NCT03678779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Video-based brief nutrition education
Study NCT03678779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined
Description: Both Incentive and Education interventions received
Study NCT02582918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outreach with patient education and patient navigation services
Description: * Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.~* Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.~* If results are normal, the patient is invited to repeat screening in 6 months.~* If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.~* If CT/MRI is unremarkable, the patient is referred back for routine screening.~* If HCC is confirmed, the patient and their primary care provider will be contacted with the results.~* All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic.
Study NCT01372124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
Study NCT03580564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KL-A167
Description: KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Study NCT00888784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Cyanoacrylate injection
Description: Endoscopic Cyanoacrylate injection in gastric varix
Study NCT00888784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: beta-blocker (propranolol)
Description: Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \<90 mm Hg or pulse rate \<55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study NCT02826291 — intervention group
Intervention type: DEVICE
Intervention: RD-100i, OSNA
Description: quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
Study NCT04380675 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Music listening during ESWL
Study NCT02645344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Study NCT02645344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Cueing (SC)
Study NCT02645344 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Study NCT02645344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Rehabilitation
Study NCT02780167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 10 mg of PF-04965842 QD for 12 weeks
Study NCT02780167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 30 mg of PF-04965842 QD for 12 weeks
Study NCT02780167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 100 mg of PF-04965842 QD for 12 weeks
Study NCT02780167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04965842
Description: 200 mg of PF-04965842 QD for 12 weeks
Study NCT02376517 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
Study NCT05283616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim 3mg per chemotherapy cycle
Study NCT05283616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegfilgrastim
Description: Pegfilgrastim 3mg per chemotherapy cycle
Study NCT04608955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WX-081
Description: WX-081 is not licensed yet. WX-081 will be used in arms A, B, C, WX-081+MBT.
Study NCT04608955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: This licensed drug will be used in arm F as positive comparator.
Study NCT04608955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard treatment will be used in arm D as positive comparator, according to the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Study NCT04608955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-drug background treatment (MBT)
Description: MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Study NCT04608955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-drug background treatment (MBT)
Description: MBT will be used in arm E, F as background treatment. The drugs used in MBT are all licensed drugs, and the treatment complies with the recommendations of WHO guidelines for diagnosis and treatment of tuberculosis.
Study NCT04352803 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose MSC's
Description: Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV
Study NCT03612882 — intervention group
Intervention type: OTHER
Intervention: Online questionnaire
Description: Online questionnaire assessing sedentary behaviour, physical activity, subjective well-being, life satisfaction, depression, anxiety, and demographics
Study NCT00354640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: 1 milligram tablet PO QD for 14 days
Study NCT00354640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 40 milligram tablet PO QD for 14 days
Study NCT00354640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: laboratory analysis
Study NCT00354640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: laboratory analysis
Study NCT01772420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag Olamine
Description: Given PO
Study NCT01772420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01772420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01240837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arenga Pinnata Sugar
Description: 50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
Study NCT01240837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
Study NCT01240837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
Study NCT02894151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot medroxyprogesterone acetate
Study NCT02894151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Study NCT00590707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deeper sedation
Description: The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
Study NCT00590707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moderate sedation
Description: The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
Study NCT01982136 — intervention group
Intervention type: PROCEDURE
Intervention: end-to-end urethroplasty
Study NCT01982136 — intervention group
Intervention type: PROCEDURE
Intervention: substitution urethroplasty (buccal mucosa)
Study NCT01982136 — intervention group
Intervention type: PROCEDURE
Intervention: substitution urethroplasty (pedicled skin flap)
Study NCT02891278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.~Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg every morning (QAM) and 100 mg every evening (QPM), 100 mg twice a day. 100 mg QAM and 150 mg QPM.
Study NCT02891278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside
Description: Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.~Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours).
Study NCT02891278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
Study NCT02662855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WHO-recommended therapies
Description: symptomatic and supportive treatments according to the WHO manual
Study NCT02662855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO-recommended therapies
Description: symptomatic and supportive treatments according to the WHO manual
Study NCT02662855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: oral administration of Favipiravir tablets
Study NCT05345119 — intervention group
Intervention type: DRUG
Intervention: Sirolimus
Description: 2 mg orally on the first day followed by 0.5 mg per day for 12 weeks
Study NCT05345119 — intervention group
Intervention type: DRUG
Intervention: Methylprednisolone
Description: 500 mg/weekly (6 weeks) intravenously, 250 mg/weekly (6 weeks) (cumulative dose 4.5 g).
Study NCT03416842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with 4D Motion Capture Device
Description: Participants will be given access to a tablet-based application and non-invasive sensors that will track movements of the upper extremity and will prompt daily exercise. Participants will be encouraged to use the device daily for 30 consecutive days, up to one hour per day.
Study NCT04195568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surpass Evolve Flow Diverter System
Description: The Surpass Evolve Flow Diverter System is indicated for the endovascular treatment of adults (age 18 or above) with unruptured saccular wide-neck or fusiform intracranial aneurysms ≤12 mm.